JP2016514672A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514672A5
JP2016514672A5 JP2016501829A JP2016501829A JP2016514672A5 JP 2016514672 A5 JP2016514672 A5 JP 2016514672A5 JP 2016501829 A JP2016501829 A JP 2016501829A JP 2016501829 A JP2016501829 A JP 2016501829A JP 2016514672 A5 JP2016514672 A5 JP 2016514672A5
Authority
JP
Japan
Prior art keywords
vaccine
antigen
nucleic acid
subject
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/025348 external-priority patent/WO2014151279A1/en
Publication of JP2016514672A publication Critical patent/JP2016514672A/ja
Publication of JP2016514672A5 publication Critical patent/JP2016514672A5/ja
Pending legal-status Critical Current

Links

JP2016501829A 2013-03-15 2014-03-13 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン Pending JP2016514672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788942P 2013-03-15 2013-03-15
US61/788,942 2013-03-15
PCT/US2014/025348 WO2014151279A1 (en) 2013-03-15 2014-03-13 Vaccines having an antigen and interleukin-23 as an adjuvant

Publications (2)

Publication Number Publication Date
JP2016514672A JP2016514672A (ja) 2016-05-23
JP2016514672A5 true JP2016514672A5 (enExample) 2017-03-30

Family

ID=51580923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501829A Pending JP2016514672A (ja) 2013-03-15 2014-03-13 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン

Country Status (8)

Country Link
US (1) US9669091B2 (enExample)
EP (1) EP2968500A4 (enExample)
JP (1) JP2016514672A (enExample)
KR (1) KR20150128900A (enExample)
CN (1) CN105209063A (enExample)
AU (1) AU2014235120B2 (enExample)
CA (1) CA2898237A1 (enExample)
WO (1) WO2014151279A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160066033A (ko) * 2013-10-07 2016-06-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 어쥬번트로서 인터류킨-33을 갖는 백신
WO2019151759A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 백신 면역보조제
CN108383913A (zh) * 2018-02-12 2018-08-10 四川大学 重组猪il-23增强pcv2疫苗免疫佐剂的制备及应用
KR102285977B1 (ko) * 2019-03-15 2021-08-05 대한민국 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물
JP2023504659A (ja) 2019-12-03 2023-02-06 ニューボーゲン，インコーポレイティド 腫瘍細胞ワクチン
TW202146435A (zh) * 2020-03-04 2021-12-16 美商昂科賽醫藥公司 含有病原性抗原及免疫刺激物之組合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
CA2478930A1 (en) 2002-04-01 2003-10-16 Euro-Celtique, S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
WO2007027860A2 (en) * 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
US20080260765A1 (en) 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
CA2805653A1 (en) * 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
CN107412756A (zh) * 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
US8802076B2 (en) * 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
EP2791157A4 (en) * 2011-12-12 2015-10-14 Univ Pennsylvania COMPOSITIONS WITH IMPROVED GENETIC IL-12 CONSTRUCTS AND VACCINES, IMMUNOTHERAPY THEREOF AND METHOD OF USE THEREOF
CN102876684B (zh) * 2012-09-17 2014-10-08 青岛康立泰药业有限公司 人白细胞介素-12的编码基因、真核宿主细胞和表达方法

Similar Documents

Publication Publication Date Title
JP2016520530A5 (enExample)
JP2016514672A5 (enExample)
Crisci et al. Virus-like particles: the new frontier of vaccines for animal viral infections
JP2019526580A5 (enExample)
JP2016516723A5 (enExample)
FI4023249T3 (fi) Nukleiinihapporokotteita
HK1254344A1 (zh) 抗原匹配的流感疫苗
JP2016506416A5 (enExample)
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
CN106659777A8 (zh) 免疫原性组合产品
JP2013507907A5 (enExample)
JP2015501840A5 (enExample)
Rezaei et al. Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials
Vemula et al. Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time
WO2008060385A3 (en) Li-key enhanced vaccine potency
Garg et al. Development of novel carrier (s) mediated tuberculosis vaccine: More than a tour de force
JP2010506926A5 (enExample)
JP2014139185A5 (enExample)
JP2019505567A5 (enExample)
JP2018501258A5 (enExample)
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
WO2011038473A8 (pt) Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same
CN103316357B (zh) 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法
PH12014502085A1 (en) Modified marek`s disease virus, and vaccines made therefrom